Cited by 7,449Lipoproteins and Cardiovascular HealthAcute Myocardial Infarction ResearchCancer, Lipids, and Metabolism

The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.

Prevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia

Open access

Shepherd, James, Cobbe, Stuart M., Ford, Ian, Isles, Christopher G., Lorimer, A. Ross, Macfarlane, Peter W., McKillop, James H., Packard, Christopher J.·1995·New England Journal of Medicine

DOI 10.1056/nejm199511163332001

Open this paper in CoChat — free account Open PDF

Abstract

BACKGROUND: Lowering the blood cholesterol level may reduce the risk of coronary heart disease. This double-blind study was designed to determine whether the administration of pravastatin to men with hypercholesterolemia and no history of myocardial infarction reduced the combined incidence of nonfatal myocardial infarction and death from coronary heart disease. METHODS: We randomly assigned 6595 men, 45 to 64 years of age, with a mean (+/- SD) plasma cholesterol level of 272 +/- 23 mg per deciliter (7.0 +/- 0.6 mmol per liter) to receive pravastatin (40 mg each evening) or placebo. The average follow-up period was 4.9 years. Medical records, electrocardiographic recordings, and the national death registry were used to determine the clinical end points. RESULTS: Pravastatin lowered plasma cholesterol levels by 20 percent and low-density-lipoprotein cholesterol levels by 26 percent, whereas there was no change with placebo. There were 248 definite coronary events (specified as nonfatal myocardial infarction or death from coronary heart disease) in the placebo group, and 174 in the pravastatin group (relative reduction in risk with pravastatin, 31 percent; 95 percent confidence interval, 17 to 43 percent; P < 0.001). There were similar reductions in the risk of definite nonfatal myocardial infarctions (31 percent reduction, P < 0.001), death from coronary heart disease (definite cases alone: 28 percent reduction, P = 0.13; definite plus suspected cases: 33 percent reduction, P = 0.042), and death from all cardiovascular causes (32 percent reduction, P = 0.033). There was no excess of deaths from noncardiovascular causes in the pravastatin group. We observed a 22 percent reduction in the risk of death from any cause in the pravastatin group (95 percent confidence interval, 0 to 40 percent; P = 0.051). CONCLUSIONS: Treatment with pravastatin significantly reduced the incidence of myocardial infarction and death from cardiovascular causes without adversely affecting the risk of death from noncardiovascular causes in men with moderate hypercholesterolemia and no history of myocardial infarction.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1056/nejm199511163332001

Cites

26 of 26 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II)
Grundy, S. M., Bilheimer, D. W., Chait, A., Clark, L. T., Denke, M. A., Havel, R. J., Hazzard, W. R., Hulley, S. B., Hunninghake, D. B., Kreisberg, R. A., et al. (1993) · JAMA · doi:10.1001/jama.269.23.3015 · Cited by 27,944
Helsinki Heart Study: Primary-Prevention Trial with Gemfibrozil in Middle-Aged Men with Dyslipidemia
Frick, M. H., Elo, O., Haapa, K., Heinonen, O. P., Heinsalmi, P., Helo, P., Huttunen, J. K., Kaitaniemi, P., Koskinen, P., Manninen, V., et al. (1987) · New England Journal of Medicine · doi:10.1056/nejm198711123172001 · Cited by 3,881
A Multiple Testing Procedure for Clinical Trials
O'Brien, P. C., & Fleming, T. R. (1979) · Biometrics · doi:10.2307/2530245 · Cited by 3,311
The Lipid Research Clinics Coronary Primary Prevention Trial Results: I. Reduction in Incidence of Coronary Heart Disease
(1984) · JAMA · doi:10.1001/jama.1984.03340270029025 · Cited by 2,747
MRC trial of treatment of mild hypertension: principal results. Medical Research Council Working Party.
(1985) · BMJ · doi:10.1136/bmj.291.6488.97 · Cited by 1,491
Modelling Survival Data in Medical Research
Collett, D. (1994) · Springer eBooks · doi:10.1007/978-1-4899-3115-3 · Cited by 1,064
A co-operative trial in the primary prevention of ischaemic heart disease using clofibrate. Report from the Committee of Principal Investigators.
Oliver, M., Heady, J., Morris, J. N., Cooper, J., Geizerova, H., Gyárfás, I., Green, K., Strasser, T., Macfie, W. G., Scott, E., et al. (1978) · Heart · doi:10.1136/hrt.40.10.1069 · Cited by 1,047
Modelling Survival Data in Medical Research.
McLachlan, G. J., & Collett, D. (1994) · Biometrics · doi:10.2307/2533471 · Cited by 1,023
Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The Regression Growth Evaluation Statin Study (REGRESS).
Jukema, J., Bruschke, A. V., van Boven, A. J., Reiber, J., Bal, E., Zwinderman, A., Jansen, H., Boerma, G., van Rappard, F. M., & Kong, L. I. (1995) · Circulation · doi:10.1161/01.cir.91.10.2528 · Cited by 911
Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Asymptomatic Carotid Artery Progression Study (ACAPS) Research Group.
Furberg, C. D., Adams, H. P., Applegate, W. B., Byington, R. P., Espeland, M. A., Hartwell, T., Hunninghake, D. B., Lefkowitz, D. S., Probstfield, J. L., & Riley, W. A. (1994) · Circulation · doi:10.1161/01.cir.90.4.1679 · Cited by 865

Show all 26 references

Research works printed but not linked: 4

10.1001/jama.251.3.351 · DOI · Paper page
1994, Lancet, 344, 1383
1992, Nutr Metab Cardiovasc Dis, 2, 113
Macfarlane PW, 1990, Eur Heart J, 11, 411

Sorted by citations

Items 1,001–1,060 of 1,060

The role of fibrates in managing hyperlipidemia: Mechanisms of action and clinical efficacy
Fazio, S., & Linton, M. F. (2004) · Current Atherosclerosis Reports · doi:10.1007/s11883-004-0104-8 · Cited by 118
Evolution of the Lipid Trial Protocol of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial
Ginsberg, H. N., Bonds, D. E., Lovato, L. C., Crouse, J. R., Elam, M. B., Linz, P. E., O’Connor, P. J., Leiter, L. A., Weiss, D., Lipkin, E., et al. (2007) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2007.03.024 · Cited by 95
Cholesterol-independent Effects of Statins and New Therapeutic Targets: Ischemic Stroke and Dementia
Miida, T., Hirayama, S., & Nakamura, Y. (2004) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.11.253 · Cited by 97
Genetic variation in the ABCA1 gene, HDL cholesterol, and risk of ischemic heart disease in the general population
Frikke-Schmidt, R. (2010) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2009.06.005 · Cited by 94
Serum Lipid Survey and Its Recent Trend in the General Japanese Population in 2000
Arai, H., Yamamoto, A., Matsuzawa, Y., Saito, Y., Yamada, N., Oikawa, S., Mabuchi, H., Teramoto, T., Sasaki, J., Nakaya, N., et al. (2005) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.12.98 · Cited by 94
The Effect of HMG-CoA Reductase Inhibitors on Coenzyme Q10: Possible Biochemical/Clinical Implications
Hargreaves, I. P., Duncan, A. J., Heales, S. J. R., & Land, J. M. (2005) · Drug Safety · doi:10.2165/00002018-200528080-00002 · Cited by 91
LDL-Apheresis: Technical and Clinical Aspects
Bambauer, R., Bambauer, C., Lehmann, B., Latza, R., & Schiel, R. (2012) · The Scientific World Journal · doi:10.1100/2012/314283 · Cited by 91
Electron beam tomography and National Cholesterol Education Program guidelines in asymptomatic women
Hecht, H. S., & Superko, H. R. (2001) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(01)01211-6 · Cited by 88
Statin Trials, Cardiovascular Events, and Coronary Artery Calcification
Mortensen, M. B., Falk, E., Li, D., Nasir, K., Blaha, M. J., Sandfort, V., Rodriguez, C. J., Ouyang, P., & Budoff, M. (2018) · JACC: Cardiovascular Imaging · doi:10.1016/j.jcmg.2017.01.029 · Cited by 88
Nonfasting Triglycerides, Low-Density Lipoprotein Cholesterol, and Heart Failure Risk: Two Cohort Studies of 113 554 Individuals
Varbo, A., & Nordestgaard, B. G. (2018) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.117.310269 · Cited by 83
Treatment options for the management of hypertriglyceridemia: strategies based on the best-available evidence
Maki, K. C., Bays, H. E., & Dicklin, M. R. (2012) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2012.04.003 · Cited by 83
The safety of HMG-CoA reductase inhibitors in special populations at high cardiovascular risk
Corsini, A. (2003) · Cardiovascular Drugs and Therapy · doi:10.1023/a:1026132412074 · Cited by 82
Heart rate variability and plasma lipids in men with and without ischaemic heart disease
Christensen, J. H., Toft, E., Christensen, M. S., & Schmidt, E. B. (1999) · Atherosclerosis · doi:10.1016/s0021-9150(99)00052-0 · Cited by 80
Enhancing Drug Compliance in Lipid-Lowering Treatment
LaRosa, J. H. (2000) · Archives of Family Medicine · doi:10.1001/archfami.9.10.1169 · Cited by 77
Statins: an essential component in the management of carotid artery disease
Paraskevas, K. I., Hamilton, G., & Mikhailidis, D. P. (2007) · Journal of Vascular Surgery · doi:10.1016/j.jvs.2007.03.035 · Cited by 77
Influence of atorvastatin and simvastatin on apolipoprotein B metabolism in moderate combined hyperlipidemic subjects with low VLDL and LDL fractional clearance rates
Forster, L. F., Stewart, G., Bedford, D., Stewart, J. P., Rogers, E., Shepherd, J., Packard, C. J., & Caslake, M. J. (2002) · Atherosclerosis · doi:10.1016/s0021-9150(02)00052-7 · Cited by 77
Self-citation
The Efficacy of Squalene in Cardiovascular Disease Risk-A Systematic Review
Ibrahim, N. ‘., Fairus, S., Zulfarina, M. S., & Naina Mohamed, I. (2020) · Nutrients · doi:10.3390/nu12020414 · Cited by 79
Pleiotropic Effects of Statins: Evidence Against Benefits Beyond LDL-Cholesterol Lowering
Pedersen, T. R. (2010) · American Journal Cardiovascular Drugs · doi:10.2165/1158822-s0-000000000-00000 · Cited by 74
A Comparison of Low Versus Standard Dose Pravastatin Therapy for the Prevention of Cardiovascular Events in the Elderly : The Pravastatin Anti-atherosclerosis Trial in the Elderly (PATE)
Ito, H., Ouchi, Y., Ohashi, Y., Saito, Y., Ishikawa, T., Nakamura, H., & Orimo, H. (2001) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat1994.8.33 · Cited by 73
Association of lowering low-density lipoprotein cholesterol with contemporary lipid-lowering therapies and risk of diabetes mellitus: a systematic review and meta-analysis
Khan, S. U., Rahman, H., Okunrintemi, V., Riaz, H., Khan, M. S., Sattur, S., Kaluski, E., Lincoff, A. M., Martin, S. S., & Blaha, M. J. (2019) · Journal of the American Heart Association · doi:10.1161/jaha.118.011581 · Cited by 70
Alterations in mood after changing to a low-fat diet
Wells, A. S., Read, N. W., Laugharne, J. D. E., & Ahluwalia, N. S. (1998) · British Journal Of Nutrition · doi:10.1079/bjn19980005 · Cited by 67
A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular outcomes
Khan, S. U., Talluri, S., Riaz, H., Rahman, H., Nasir, F., Bin Riaz, I., Sattur, S., Ahmed, H., Kaluski, E., & Krasuski, R. (2018) · European Journal of Preventive Cardiology · doi:10.1177/2047487318766612 · Cited by 61
Nonstatin Low-Density Lipoprotein–Lowering Therapy and Cardiovascular Risk Reduction—Statement From ATVB Council
Hegele, R. A., Gidding, S. S., Ginsberg, H. N., McPherson, R., Raal, F. J., Rader, D. J., Robinson, J. G., & Welty, F. K. (2015) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.115.306442 · Cited by 63
Cholesterol Reduction and Clinical Benefit: Are There Limits to Our Expectations?
Fager, G., & Wiklund, O. (1997) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.17.12.3527 · Cited by 62
Diagnosis and Treatment of Heart Disease: Are Women Different From Men?
Xhyheri, B., & Bugiardini, R. (2010) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2010.07.004 · Cited by 56
Do statins reduce the risk of myocardial infarction in patients with heart failure? A pooled individual-level reanalysis of CORONA and GISSI-HF
Feinstein, M. J., Jhund, P., Kang, J., Ning, H., Maggioni, A., Wikstrand, J., Kjekshus, J., Tavazzi, L., McMurray, J., & Lloyd-Jones, D. M. (2015) · European Journal of Heart Failure · doi:10.1002/ejhf.247 · Cited by 56
ApoCIII as a cardiovascular risk factor and modulation by the novel lipid-lowering agent volanesorsen
Rocha, N. A., East, C., Zhang, J., & McCullough, P. A. (2017) · Current Atherosclerosis Reports · doi:10.1007/s11883-017-0697-3 · Cited by 54
Relationship Between Serum Cholesterol and the Risk of Acute Myocardial Infarction in a Screened Cohort in Okinawa, Japan
wakugami, K., Iseki, K., Kimura, Y., Okumura, K., lkemiya, Y., Muratani, H., & Fukiyama, K. (1998) · Japanese Circulation Journal · doi:10.1253/jcj.62.7 · Cited by 51
Intensity of Statin Therapy, Achieved Low-Density Lipoprotein Cholesterol Levels and Cardiovascular Outcomes in Japanese Patients After Coronary Revascularization: – Perspectives From the CREDO-Kyoto Registry Cohort-2 –
Natsuaki, M., Furukawa, Y., Morimoto, T., Nakagawa, Y., Ono, K., Kaburagi, S., Inada, T., Mitsuoka, H., Taniguchi, R., Nakano, A., et al. (2012) · Circulation Journal · doi:10.1253/circj.cj-11-1356 · Cited by 49
Potential cost-effectiveness of C-reactive protein screening followed by targeted statin therapy for the primary prevention of cardiovascular disease among patients without overt hyperlipidemia
Blake, G. J., Ridker, P. M., & Kuntz, K. M. (2003) · The American Journal of Medicine · doi:10.1016/s0002-9343(03)00074-3 · Cited by 44
Effects of Hibiscus sabdariffa L. on serum lipids: A systematic review and meta-analysis
Aziz, Z., Wong, S. Y., & Chong, N. J. (2013) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2013.09.042 · Cited by 44
Utility of genetic determinants of lipids and cardiovascular events in assessing risk
Holmes, M. V., Harrison, S., Talmud, P. J., Hingorani, A. D., & Humphries, S. E. (2011) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2011.6 · Cited by 44
Interventions to improve adherence to lipid-lowering medication
van Driel, M. L., Morledge, M. D., Ulep, R., Shaffer, J. P., Davies, P., & Deichmann, R. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004371.pub4 · Cited by 333
High-risk elderly patients PROSPER from cholesterol-lowering therapy
Collins, R., & Armitage, J. (2002) · The Lancet · doi:10.1016/s0140-6736(02)11650-3 · Cited by 42
Perspectives on low-density-lipoprotein cholesterol goal achievement
Catapano, A. L. (2009) · Current Medical Research and Opinion · doi:10.1185/03007990802631438 · Cited by 40
Global mapping of randomised trials related articles published in high-impact-factor medical journals: a cross-sectional analysis
Catalá-López, F., Aleixandre-Benavent, R., Caulley, L., Hutton, B., Tabarés-Seisdedos, R., Moher, D., & Alonso-Arroyo, A. (2020) · Trials · doi:10.1186/s13063-019-3944-9 · Cited by 38
Apolipoprotein profiling as a personalized approach to the diagnosis and treatment of dyslipidaemia
Renee Ruhaak, L., van der Laarse, A., & Cobbaert, C. M. (2019) · Annals of Clinical Biochemistry: International Journal of Laboratory Medicine · doi:10.1177/0004563219827620 · Cited by 38
Triglycerides and non-high-density lipoprotein cholesterol and the incidence of cardiovascular disease in an urban Japanese cohort: The Suita study
Okamura, T., Kokubo, Y., Watanabe, M., Higashiyama, A., Ono, Y., Miyamoto, Y., Yoshimasa, Y., & Okayama, A. (2010) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2009.09.012 · Cited by 35
Renal Function and Effect of Statin Therapy on Cardiovascular Outcomes in Patients Undergoing Coronary Revascularization (from the CREDO-Kyoto PCI/CABG Registry Cohort-2)
Natsuaki, M., Furukawa, Y., Morimoto, T., Sakata, R., & Kimura, T. (2012) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2012.07.021 · Cited by 35
Risk factors for stroke and lipid-lowering effect of pravastatin on the risk of stroke in Japanese patients with hypercholesterolemia: Analysis of data from the MEGA Study, a large randomized controlled trial
Uchiyama, S., Nakaya, N., Mizuno, K., Ohashi, Y., Tajima, N., Kushiro, T., Teramoto, T., & Nakamura, H. (2009) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2009.04.002 · Cited by 32
The cost effectiveness of statin therapies in Spain in 2010, after the introduction of generics and reference prices
Plans-Rubió, P. (2010) · American Journal Cardiovascular Drugs · doi:10.2165/11539150-000000000-00000 · Cited by 31
Clinical profile of statin intolerance in the phase 3 GAUSS-2 Study
Cho, L., Rocco, M., Colquhoun, D., Sullivan, D., Rosenson, R. S., Dent, R., Xue, A., Scott, R., Wasserman, S. M., & Stroes, E. (2016) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-016-6655-4 · Cited by 30
Statin-induced myopathy in a usual care setting—a prospective observational study of gender differences
Skilving, I., Eriksson, M., Rane, A., & Ovesjö, M.-L. (2016) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-016-2105-2 · Cited by 28
Role of colesevelam in combination lipid-lowering therapy
Jones, M. R., & Nwose, O. M. (2013) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-013-0037-0 · Cited by 27
Coronary Risk Factor Profile and Prognostic Factors for Young Japanese Patients Undergoing Coronary Revascularization
Furukawa, Y., Ehara, N., Taniguchi, R., Haruna, Y., Ozasa, N., Saito, N., Doi, T., Hoshino, K., Tamura, T., Shizuta, S., et al. (2009) · Circulation Journal · doi:10.1253/circj.cj-08-1083 · Cited by 25
Socioeconomic Status Correlates with the Prevalence of Advanced Coronary Artery Disease in the United States
Bashinskaya, B., Nahed, B. V., Walcott, B. P., Coumans, J.-V. C. E., & Onuma, O. K. (2012) · PLoS ONE · doi:10.1371/journal.pone.0046314 · Cited by 27
Low-density lipoprotein apheresis as a treatment option for hyperlipidemia
Mehta, P. K., Baer, J., Nell, C., & Sperling, L. S. (2009) · Current Treatment Options in Cardiovascular Medicine · doi:10.1007/s11936-009-0029-1 · Cited by 26
Better Survival With Statin Administration After Revascularization Therapy in Japanese Patients With Coronary Artery Disease Perspectives From the CREDO-Kyoto Registry
Furukawa, Y., Taniguchi, R., Ehara, N., Ozasa, N., Haruna, Y., Saito, N., Doi, T., Hoshino, K., Shizuta, S., Morimoto, T., et al. (2008) · Circulation Journal · doi:10.1253/circj.cj-08-0293 · Cited by 25
Lowering LDL cholesterol in adults: a prospective, community-based practice initiative
Coodley, G. O., Jorgensen, M., Kirschenbaum, J., Sparks, C., Zeigler, L., & Albertson, B. D. (2008) · The American Journal of Medicine · doi:10.1016/j.amjmed.2008.02.031 · Cited by 23
Statins for Primary Prevention: The Debate Is Intense, but the Data Are Weak
Redberg, R. F., & Katz, M. H. (2017) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2016.7585 · Cited by 22
ESSENS dyslipidemia: A placebo-controlled, randomized study of a nutritional supplement containing red yeast rice in subjects with newly diagnosed dyslipidemia
Kasliwal, R. R., Bansal, M., Gupta, R., Shah, S., Dani, S., Oomman, A., Pai, V., Prasad, G. M., Singhvi, S., Patel, J., et al. (2016) · Nutrition · doi:10.1016/j.nut.2016.01.012 · Cited by 17
Cardiovascular risk reduction in African Americans: Current concepts and controversies
Ferdinand, K. C. (2016) · Global Cardiology Science and Practice · doi:10.21542/gcsp.2016.2 · Cited by 14
The Impact of Pravastatin Therapy on Long-Term Outcome in Patients With Metabolic Syndrome Undergoing Complete Coronary Revascularization
Kasai, T., Miyauchi, K., Kajimoto, K., Kubota, N., Kurata, T., Amano, A., & Daida, H. (2009) · Circulation Journal · doi:10.1253/circj.cj-09-0122 · Cited by 13
Economic evaluation of primary prevention of cardiovascular diseases in mild hypertension: a scenario analysis for the Netherlands
Stevanović, J., O’Prinsen, A. C., Verheggen, B. G., Schuiling-Veninga, N., Postma, M. J., & Pechlivanoglou, P. (2014) · Clinical Therapeutics · doi:10.1016/j.clinthera.2014.01.008 · Cited by 12
The Relationship Between Low-Density Lipoprotein Cholesterol Levels and the Incidence of Cardiovascular Disease in High-Risk Patients Treated With Pravastatin: Main Results of the APPROACH-J Study
Daida, H., Teramoto, T., Kitagawa, Y., Matsushita, Y., Sugihara, M., & APPROACH-J Study Group (2014) · International Heart Journal · doi:10.1536/ihj.13-002 · Cited by 12
Effects of Chronic Combined Treatment With Captopril and Pravastatin on the Progression of Insulin Resistance and Cardiovascular Alterations in an Experimental Model of Obesity in Dogs
Villa, E., Rabano, A., Albarran, O. G., Ruilope, L. M., & Garcia-Robles, R. (1998) · American Journal of Hypertension · doi:10.1016/s0895-7061(98)00053-3 · Cited by 11
Improving effect of ethyl eicosapentanoate on statin-induced rhabdomyolysis in Eisai hyperbilirubinemic rats
Naba, H., Kakinuma, C., Ohnishi, S., & Ogihara, T. (2006) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.11.179 · Cited by 10
Misrepresentation of statin safety evidence
Armitage, J., Baigent, C., & Collins, R. (2014) · The Lancet · doi:10.1016/s0140-6736(14)61765-7 · Cited by 10
Comparison of Transcriptomic Profiles of MiaPaCa-2 Pancreatic Cancer Cells Treated with Different Statins
Rimpelová, S., Kolář, M., Strnad, H., Ruml, T., Vítek, L., & Gbelcová, H. (2021) · Molecules · doi:10.3390/molecules26123528 · Cited by 8
A Proposal for the Optimal Management Target for Serum Non-High-Density Lipoprotein Cholesterol Level in Low-Risk Japanese Workers
Saiki, Y., Otsuka, T., Kato, K., & Kawada, T. (2016) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.33068 · Cited by 7

Authors: Shepherd, J., Cobbe, S. M., Ford, I., Isles, C. G., Lorimer, A. R., Macfarlane, P. W., McKillop, J. H., & Packard, C. J.
Affiliations: Glasgow Royal Infirmary (GB)
University of Glasgow (GB)
NHS Dumfries and Galloway (GB)
ORCID: Ford, Ian
Macfarlane, Peter W.
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 1995-11-16
Volume: 333
Issue: 20
Pages: 1301-1308
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejm199511163332001
OpenAlex: W2155598961
Semantic Scholar: 1aa5f64bbe1d0c4c74fc3de7c89ac2dffb48630a
Cited by: 7,449
References: 26
Citations by year: 2026: 31 · 2025: 33 · 2024: 56 · 2023: 54 · 2022: 66 · 2021: 72 · 2020: 95 · 2019: 90 · 2018: 108 · 2017: 121 · 2016: 157 · 2015: 137 · 2014: 177 · 2013: 215 · 2012: 197
FWCI: 344.87
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: New England Journal of Medicine (publishedVersion)
PubMed (publishedVersion)
Funders: Bristol-Myers Squibb
Topics: Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
Keywords: pravastatin, hypercholesterolemia, coronary heart disease prevention, statins, LDL cholesterol lowering, nonfatal myocardial infarction, cardiovascular mortality, men, cholesterol-lowering therapy
MeSH terms: Anticholesteremic Agents, Cholesterol, Coronary Disease, Double-Blind Method, Humans, Hypercholesterolemia, Cholesterol, LDL, Male, Middle Aged, Myocardial Infarction, Neoplasms, Risk, Incidence, Survival Analysis, Pravastatin

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Prevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks